Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies, being the 7th leading cause of cancer-related mortality worldwide. PDAC remains associated with an extremely poor prognosis, owing to drug resistance and to the lack of alternative therapeutic options. Standard chemotherapy typically involves gemcitabine, either alone or combined with paclitaxel. Moreover, Chitinase-...